- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02238028
Short-term Cardiovascular Benefits of Wearing Particulate-filtering Respirators
April 6, 2016 updated by: Haidong Kan, Fudan University
Short-term Cardiovascular Benefits of Wearing Particulate-filtering Respirators: a Randomized Controlled Crossover Trial Among Healthy Young Adults
An intervention study to assess the short-term cardiovascular effects of reducing personal air pollution exposure by wearing particulate filtering respirators.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
A group of healthy adult college students fulfilling the recruitment criteria were randomly divided into two sub-groups.
One sub-group weared the particulate filtering respirators for 2 continuous days during which the respirator was required to wear as much as possible both indoor and outdoor.
The other group acted as normal at the same time.
The measurements on health effects including heart rate varibility, blood pressure, circulating biomarkers as well as the ambient air pollution were performed in both groups during the intervention period.
After a 3-week rest period,the two groups interchanged their roles of wearing the respirator or not.
The same measurements of both health effects indicators and ambient air pollution were repeated.
Study Type
Interventional
Enrollment (Actual)
28
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200032
- Department of Environmental Health, School of Public Health, Fudan University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 35 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Equal to or older than 18 years old,
- No history of smoking and alcohol addiction.
- No chronic diseases,such as hypertension,diabetes,chronic obstructive pulmonary disease or other respiratory/cardiovascular diseases reported by volunteers.
- No respiratory or allergic diseases, like asthma, rhinitis,or other allergic diseases.
Exclusion Criteria:
- Current smokers
- Chronic drug use due on cardiovascular or respiratory diseases
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Wear respirator
The recruited healthy subjects were randomly allocated into two groups.In each intervention, one group wore the high-efficiency respirator as much as possible for continuous 48hr and the other group behaved as usual.
After a three-week interval, the two groups exchanged their roles in wearing the respirator or not.
The same protocol on the measurements of health indicators and ambient air pollution was applied in the 1st intervention and 2nd intervention period.
|
Healthy adult subjects wore the particulate filtering respirators for continuous 48 hours as much as possible both indoor and outdoor.
Other Names:
|
|
No Intervention: Not wear respirator
The recruited healthy subjects were randomly allocated into two groups.In each intervention, one group wore the high-efficiency respirator as much as possible for continuous 48hr and the other group behaved as usual.
After a three-week interval, the two groups exchanged their roles in wearing the respirator or not.
The same protocol on the measurements of health indicators and ambient air pollution was applied in the 1st intervention and 2nd intervention period.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Heart Rate Variability-LF Power,HF Power,VLF Power
Time Frame: up to 24 hours
|
HRV is a quantitative health marker reflecting how the autonomic nervous system modulates the sinoatrial node in the heart and HRV has therefore been widely used to estimate cardiac autonomic function and control.
Subjects were attached with Holter monitor on the 2nd day in each of the 48-hr intervention period.A total of 8 parameters of HRV were analyzed including 4 time-domain indices and 4 frequency-domain indices.
Frequency domain methods assign bands of frequency and then count the number of NN intervals that match each band.
The bands are typically high frequency (HF) from 0.15 to 0.4 Hz, low frequency (LF) from 0.04 to 0.15 Hz, and the very low frequency (VLF) from 0.0033 to 0.04 Hz.
Parasympathetic activity is a major contributor to the HF component.
More problematic is the interpretation of the LF component, which was considered by some as a marker of sympathetic modulation but is now known to include both sympathetic and vagal influences.
|
up to 24 hours
|
|
Blood Pressure
Time Frame: up to 24 hours
|
The blood pressure were measured by automatic blood pressure monitor during the intervention study.
|
up to 24 hours
|
|
Heart Rate Variability-SDNN,SDANN, rMSSD
Time Frame: Up to 24 hours
|
HRV is a quantitative health marker reflecting how the autonomic nervous system modulates the sinoatrial node in the heart and HRV has therefore been widely used to estimate cardiac autonomic function and control.A total of 8 parameters of HRV were analyzed including 4 time-domain indices and 4 frequency-domain indices.
Subjects were attached with Holter monitor on the 2nd day in each of the 48-hr intervention period.
Heart rate and heart automatic function indices including the standard deviation of the normal-to-normal interval(SDNN),the standard deviation of the average NN intervals calculated over short periods(SDANN), the root mean square of the successive differences(rMSSD) were automatically recorded during the intervention.
|
Up to 24 hours
|
|
Heart Rate Variability-LF/HF
Time Frame: Up to 24 hours
|
HRV is a quantitative health marker reflecting how the autonomic nervous system modulates the sinoatrial node in the heart and HRV has therefore been widely used to estimate cardiac autonomic function and control.
Subjects were attached with Holter monitor on the 2nd day in each of the 48-hr intervention period.A total of 8 parameters of HRV were analyzed including 4 time-domain indices and 4 frequency-domain indices.
Frequency domain methods assign bands of frequency and then count the number of NN intervals that match each band.
The bands are typically high frequency (HF) from 0.15 to 0.4 Hz, low frequency (LF) from 0.04 to 0.15 Hz.
Parasympathetic activity is a major contributor to the HF component.
More problematic is the interpretation of the LF component, which was considered by some as a marker of sympathetic modulation but is now known to include both sympathetic and vagal influences.
|
Up to 24 hours
|
|
Heart Rate Variability-pNN50
Time Frame: Up to 24 hours
|
HRV is a quantitative health marker reflecting how the autonomic nervous system modulates the sinoatrial node in the heart and HRV has therefore been widely used to estimate cardiac autonomic function and control.A total of 8 parameters of HRV were analyzed including 4 time-domain indices and 4 frequency-domain indices.
Subjects were attached with Holter monitor on the 2nd day in each of the 48-hr intervention period.
Heart rate and heart automatic function indices including the proportion of successive normal NN intervals differing by more than 50 ms in the total number of NNs(pNN50) were automatically recorded during the intervention.
|
Up to 24 hours
|
|
Circulating Biomarkers--Fibrinogen,vWF
Time Frame: Up to 24 hours
|
At the end of each intervention, participants were asked to rest in a quiet room for half an hour.
Peripheral venous blood samples were collected and centrifuged immediately.
The serum were collected and stored at -80℃ within 30 minutes to minimize the in-vitro changes in biomarker proteins.
Fibrinogen and von Willebrand factor(vWF) were measured by using the Millipore MILLIPLEX MAP human cytokine/chemokine kit (Millipore Corp., Billerica, Massachusetts)
|
Up to 24 hours
|
|
Circulating Biomarkers--P- Selectin,VCAM-1
Time Frame: Up to 24 hours
|
At the end of each intervention, participants were asked to rest in a quiet room for half an hour.
Peripheral venous blood samples were collected and centrifuged immediately.
The serum were collected and stored at -80℃ within 30 minutes to minimize the in-vitro changes in biomarker proteins.
P- selectin,VCAM-1(vascular cell adhesion molecule-1) were measured by using the Millipore MILLIPLEX MAP human cytokine/chemokine kit (Millipore Corp., Billerica, Massachusetts)
|
Up to 24 hours
|
|
Circulating Biomarkers--ET-1
Time Frame: Up to 24 hours
|
At the end of each intervention, participants were asked to rest in a quiet room for half an hour.
Peripheral venous blood samples were collected and centrifuged immediately.
The serum were collected and stored at -80℃ within 30 minutes to minimize the in-vitro changes in biomarker proteins.
Endothelin-1(ET-1) was using enzyme-linked immunosorbent assays.
|
Up to 24 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Kan Haidong, PhD, School of Public Health,Fudan University
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Chen R, Zhao A, Chen H, Zhao Z, Cai J, Wang C, Yang C, Li H, Xu X, Ha S, Li T, Kan H. Cardiopulmonary benefits of reducing indoor particles of outdoor origin: a randomized, double-blind crossover trial of air purifiers. J Am Coll Cardiol. 2015 Jun 2;65(21):2279-87. doi: 10.1016/j.jacc.2015.03.553.
- Shah AS, Langrish JP, Nair H, McAllister DA, Hunter AL, Donaldson K, Newby DE, Mills NL. Global association of air pollution and heart failure: a systematic review and meta-analysis. Lancet. 2013 Sep 21;382(9897):1039-48. doi: 10.1016/S0140-6736(13)60898-3. Epub 2013 Jul 10.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2014
Primary Completion (Actual)
October 1, 2014
Study Completion (Actual)
December 1, 2014
Study Registration Dates
First Submitted
September 7, 2014
First Submitted That Met QC Criteria
September 11, 2014
First Posted (Estimate)
September 12, 2014
Study Record Updates
Last Update Posted (Estimate)
May 6, 2016
Last Update Submitted That Met QC Criteria
April 6, 2016
Last Verified
April 1, 2016
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- KZGY 001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Inflammation
-
University of EdinburghUmeå UniversityCompletedSystemic Inflammation | Respiratory InflammationSweden
-
University of AarhusAarhus University Hospital; University of CopenhagenCompletedSystemic Inflammation | Airway InflammationDenmark
-
Sykehuset TelemarkRikshospitalet University Hospital; Helse Sor-OstCompletedAirway Inflammation | Peripheral Blood Inflammation Markers | Cement Dust ExposureNorway
-
Center for Research and Innovation Viña Concha...Universidad Católica del MauleNot yet recruitingInflammaging | Antioxidant Status, Inflammation | Inflammation Biomarkers | Antioxidant Capabilities | Cardiometabolic Health IndicatorsChile
-
University of NebraskaNot yet recruiting
-
Central Hospital, Nancy, FranceRecruiting
-
Oral Science International Inc.AdvarraNot yet recruiting
-
University of NebraskaCompletedPeriodontal InflammationUnited States
-
University of California, DavisCompleted
-
Università degli Studi di BresciaCompletedVitreous Inflammation
Clinical Trials on Wear respirator
-
Fraunhofer-Institute of Toxicology and Experimental...Completed
-
University of EdinburghPeking Union Medical CollegeCompletedBlood Pressure | Heart Rate VariabilityChina
-
University Hospitals Cleveland Medical CenterPeking University; University of MichiganCompletedAir PollutionUnited States, China
-
Becton, Dickinson and CompanyCompleted
-
Wake Forest University Health SciencesFree AirCompleted
-
Brigham and Women's HospitalMemorial Sloan Kettering Cancer Center; Massachusetts General HospitalRecruitingPersonal Protective EquipmentUnited States
-
University of South BohemiaCompletedRespiratory Complication | Face Mask SqueezeCzechia
-
McMaster UniversityUniversity of AlbertaCompletedCoronavirus | N95 | Medical MaskCanada, Egypt, Israel, Pakistan
-
Queen's UniversityThe Physicians' Services Incorporated FoundationCompletedSevere Acute Respiratory SyndromeCanada
-
BioSensicsUniversity of RochesterUnknownHuntington DiseaseUnited States